clazosentan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
endothelin receptor antagonists 5518 180384-56-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • clazosentan
  • clazosentan sodium
  • pivlaz
  • Ro 61-1790
  • AXV-034343
  • VML 588
  • ACT-108475
Clazosentan is an endothelin receptor antagonist indicated for the prevention of cerebrovascular spasm after surgery for subarachnoid hemorrhage caused by cerebral aneurysm, and cerebral infarctions and cerebral ischemic symptoms accompanying the cerebrovascular spasm.
  • Molecular weight: 577.58
  • Formula: C25H23N9O6S
  • CLOGP: 2.11
  • LIPINSKI: 2
  • HAC: 15
  • HDO: 3
  • TPSA: 200.11
  • ALOGS: -4.13
  • ROTB: 10

Drug dosage:

None

ADMET properties:

None

Approvals:

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

None

Drug Use | Suggest Off label Use Form| |View source of the data|




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

External reference:

Pharmaceutical products:

None

clazosentan